Wednesday, October 29, 2014 3:02:28 PM
IMO this is a significant overstatement and does at least loosely imply that something is in place and ready to be used.
It is also an overstatement at some significant level that even if say - Flucide and/or Ebolacide works well and works well soon - that the development model used and the development platform used would work on "ANY AND ALL viruses"
That is one of my complaints with what Harris reports when he talks about NNVC - and is one of the reasons that over the years here that many have become disenchanted with the timeline that company has taken to get to this relatively advanced testing point.
The ADIF Technology
http://www.nanoviricides.com/adiftechnology.html
Has huge amounts of potential to be adapted to a broad array of viruses. Potential and reality are two quite different things most of the time.
However - for those viruses where a good 3-D model of a cell-binding ligand can be developed (like for example those on Flucide, or potentially on Ebolacide2) - the potential to develop effective antiviral treatments is very high.
So yes - this statement is (to be kind) premature and could easily be considered deceptive.
It is important to note (however) that the statement was not made by NNVC or its insiders - but rather by an interested outsider with a history of being an avid supporter of NNVC.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM